Scott H Donaldson


Affiliation: University of North Carolina
Country: USA


  1. request reprint
    Donaldson S, Corcoran T, Laube B, Bennett W. Mucociliary clearance as an outcome measure for cystic fibrosis clinical research. Proc Am Thorac Soc. 2007;4:399-405 pubmed
    ..The resulting data may then be used to select those candidates that should be rapidly advanced into larger clinical trials. ..
  2. request reprint
    Donaldson S, Bennett W, Zeman K, Knowles M, Tarran R, Boucher R. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006;354:241-50 pubmed
    ..This treatment may protect the lung from insults that reduce mucus clearance and produce lung disease. ..
  3. Donaldson S, Solomon G, Zeitlin P, Flume P, Casey A, McCoy K, et al. Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR. J Cyst Fibros. 2017;16:371-379 pubmed publisher
    ..1mmol/L; P=0.032) at day 28. The favorable safety and clinical profile warrant further study of cavosonstat in CF. Numbers: NCT02275936, NCT02013388, NCT02500667. ..
  4. request reprint
    Donaldson S, Picher M, Boucher R. Secreted and cell-associated adenylate kinase and nucleoside diphosphokinase contribute to extracellular nucleotide metabolism on human airway surfaces. Am J Respir Cell Mol Biol. 2002;26:209-15 pubmed
  5. request reprint
    Donaldson S, Hirsh A, Li D, Holloway G, Chao J, Boucher R, et al. Regulation of the epithelial sodium channel by serine proteases in human airways. J Biol Chem. 2002;277:8338-45 pubmed
    ..These data, therefore, suggest that protease-mediated regulation of sodium absorption is a function of human airway epithelia, and prostasin is a likely candidate for this activity. ..
  6. Donaldson S, Pilewski J, Griese M, Cooke J, Viswanathan L, Tullis E, et al. Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR. Am J Respir Crit Care Med. 2017;: pubmed publisher
    ..05 for all). These results support continued clinical development of tezacaftor 100 mg qday in combination with ivacaftor 150 mg q12h in subjects with CF. Clinical trial registration available at, ID NCT0153167. ..